Cardiovascular Events Associated With Ipratropium Bromide in COPD


      Studies have suggested an increased risk of cardiovascular morbidity and mortality associated with the use of ipratropium bromide. We sought to examine the association between ipratropium bromide use and the risk of cardiovascular events (CVEs).


      We performed a cohort study of 82,717 US veterans with a new diagnosis of COPD between 1999 and 2002. Subjects were followed until they had their first hospitalization for a CVE (acute coronary syndrome, heart failure, or cardiac dysrhythmia), they died, or the end of the study period (September 30, 2004). Cumulative anticholinergic exposure was calculated as the number of 30-day equivalents (ipratropium bromide) within the past year. We used Cox regression models with time-dependent covariates to estimate the risk of CVE associated with anticholinergic exposure and to adjust for potential confounders, including markers of COPD severity and cardiovascular risk.


      We identified 6,234 CVEs (44% heart failure, 28% acute coronary syndrome, 28% dysrhythmia). Compared with subjects not exposed to anticholinergics within the past year, any exposure to anticholinergics within the past 6 months was associated with an increased risk of CVE (hazard ratio [95% CI] for≤four and>four 30-day equivalents: 1.40 [1.30–1.51] and 1.23 [1.13–1.36], respectively). Among subjects who received anticholinergics more than 6 months prior, there did not appear to be elevated risk of a CVE.


      We found an increased risk of CVEs associated with the use of ipratropium bromide within the past 6 months. These findings are consistent with previous concerns raised about the cardiovascular safety of ipratropium bromide.
      To read this article in full you will need to make a payment
      Subscribe to CHEST
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Barnes PJ
        The role of anticholinergics in chronic obstructive pulmonary disease.
        Am J Med. 2004; 117: 24S-32S
        • Tashkin DP
        • Celli B
        • Senn S
        • UPLIFT Study Investigators
        • et al.
        A 4-year trial of tiotropium in chronic obstructive pulmonary disease.
        N Engl J Med. 2008; 359: 1543-1554
        • Anthonisen NR
        • Connett JE
        • Enright PL
        • Manfreda J
        • Lung Health Study Research Group
        Hospitalizations and mortality in the Lung Health Study.
        Am J Respir Crit Care Med. 2002; 166: 333-339
        • Guite HF
        • Dundas R
        • Burney PG
        Risk factors for death from asthma, chronic obstructive pulmonary disease, and cardiovascular disease after a hospital admission for asthma.
        Thorax. 1999; 54: 301-307
        • Lee TA
        • Pickard AS
        • Au DH
        • Bartle B
        • Weiss KB
        Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease.
        Ann Intern Med. 2008; 149: 380-390
        • Macie C
        • Wooldrage K
        • Manfreda J
        • Anthonisen N
        Cardiovascular morbidity and the use of inhaled bronchodilators.
        Int J Chron Obstruct Pulmon Dis. 2008; 3: 163-169
        • Singh S
        • Loke YK
        • Furberg CD
        Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.
        JAMA. 2008; 300: 1439-1450
        • Fan VS
        • Bryson CL
        • Curtis JR
        • et al.
        Inhaled corticosteroids in chronic obstructive pulmonary disease and risk of death and hospitalization: time-dependent analysis.
        Am J Respir Crit Care Med. 2003; 168: 1488-1494
        • Lee TA
        • Bartle B
        • Weiss KB
        Spirometry use in clinical practice following diagnosis of COPD.
        Chest. 2006; 129: 1509-1515
        • Donaldson GC
        • Wedzicha JA
        COPD exacerbations. 1: Epidemiology.
        Thorax. 2006; 61: 164-168
        • Fisher LD
        • Lin DY
        Time-dependent covariates in the Cox proportional-hazards regression model.
        Annu Rev Public Health. 1999; 20: 145-157
        • Ringbaek T
        • Viskum K
        Is there any association between inhaled ipratropium and mortality in patients with COPD and asthma?.
        Respir Med. 2003; 97: 264-272
        • Salpeter SR
        • Buckley NS
        • Salpeter EE
        Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD.
        J Gen Intern Med. 2006; 21: 1011-1019
        • Hynes DM
        • Koelling K
        • Stroupe K
        • et al.
        Veterans' access to and use of Medicare and Veterans Affairs health care.
        Med Care. 2007; 45: 214-223

      Linked Article

      • Anticholinergic Drugs for the Treatment of COPD Are Safe… Are They?
        CHESTVol. 137Issue 1
        • Preview
          COPD is increasingly recognized as a complex systemic disorder with a whole range of comorbidities, especially cardiovascular, contributing significantly to COPD morbidity and mortality.1 Among the most frequently prescribed inhaled medications for this disorder are anticholinergic agents, such as short-acting ipratropium bromide, available for 20 years, and the long-acting drug tiotropium bromide, introduced in 2002, which has been shown to improve airflow, hyperinflation, exercise tolerance, exacerbations of COPD, and health-related quality of life with once-daily dosing2–8 in patients with COPD.
        • Full-Text
        • PDF